Reverb Therapeutics

Reverb Therapeutics is a biotechnology company that adjusts the volume and tunes the body’s natural immune system to improve clinical outcomes for patients with cancer and autoimmune disease. Its novel Amplify•R™ platform amplifies and redirects the body’s own cytokines to help patients without the harm associated with exogenous cytokine treatments.

“Closing this financing is an important milestone for Reverb as we move AMP01 through IND-enabling studies and towards first-in-human evaluation. We’re grateful for the strong support from InBC as we continue to build a robust pipeline of drug candidates that will have a meaningful impact for patients with high unmet medical needs.”

— David de Graaf, Ph.D, CEO of Reverb Therapeutics 

Established
2023

Purpose
To develop precision medicines for life-threatening diseases.

Year invested
2024